ARMP

News Armata Posts 59 Percent Q2 Revenue Jump

14d ago

SEC filing ARMP Secures FDA Fast Track for AP-SA02, Advances Phase 3 S. aureus Bacteremia Study, $26.2M DoD Award, Potential Accelerated Approval Pathway

26d ago

SEC filing ARMP Appoints Pfizer Exec Daniel Gilmer PhD to Board, Phage Pipeline Advances, Exebacase Fast Track

36d ago

SEC filing ARMP Posts $1.1M Grant Rev, $6.1M R&D Spend, $3.4M G&A, $5.4M Impairment, $124.3M Net Loss, $14.1M Cash, Amends $50M Credit, 36.6M Shares Outstanding

68d ago

SEC filing ARMP Delays Q4 2025 Results, Announces FDA QIDP for AP-SA02, Advances to Phase 3, Launches cGMP Facility

75d ago

Scanner Unusual volume (2.0x average)

119d ago

News Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

140d ago